Marker Therapeutics Inc (MRKR)

[Sugarshaker]

Check this out interesting, trials from clinical trials .gov.
1 Not yet recruiting Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
Condition: Platinum Sensitive Ovarian Cancer
Interventions: Biological: FRa peptide plus Adjuvant (GM-CSF); Drug: Adjuvant (GM-CSF) Alone
2 Recruiting Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Biological: Low dose FRa vaccine; Drug: Cyclophosphamide; Biological: High dose FRa vaccine
3 Recruiting TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: TPIV200; Biological: Durvalumab

Today a old trial added I thought was complete,trial 3 was listed as unknown for a long time,

1 Not yet recruiting Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
Condition: Platinum Sensitive Ovarian Cancer
Interventions: Biological: FRa peptide plus Adjuvant (GM-CSF); Drug: Adjuvant (GM-CSF) Alone
2 Recruiting Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Biological: Low dose FRa vaccine; Drug: Cyclophosphamide; Biological: High dose FRa vaccine
3 Active, not recruiting Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer; Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine; Other: laboratory biomarker analysis
4 Recruiting TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: TPIV200; Biological: Durvalumab